Our results report the underlying mechanisms of HSPA8‐mediated drug resistance to BRAF inhibitors in CRC and highlight HSPA8 as a potential biomarker and therapeutic target for BRAF V600E CRC patients. Here, HSPA8 is linked to colorectal carcinoma.